Speech by Federal Chancellor Dr. Angela Merkel at the expansion of the Takeda GmbH plant on June 16, 2017, in Oranienburg:

Germany Angela Merkel · Former Chancellor of Germany

16 June 2017 · Opening of the new production module at the Takeda GmbH plant expansion · Takeda GmbH plant, Oranienburg, Germany

Context
Merkel spoke at the expansion ceremony of the Takeda GmbH plant in Oranienburg, Brandenburg on June 16, 2017, celebrating a 100 million euro investment.
Main themes
German-Japanese economic cooperation, pharmaceutical industry investment, digitalization in healthcare, vocational training and skilled workforce, Takeda GmbH plant expansion, 3D printing in pharmaceuticals, Brandenburg industrial development, talent acquisition and STEM education, German reunification economic legacy
Duration
~14 min
48th percentile
Words
1,658
48th percentile
Sentences
96
61st percentile
Readability
45
49th percentile
Grade
11.1
33rd percentile
Syntax
2.80
22nd percentile
Vocabulary
2.16
39th percentile

Translated from German

Content
Actors
Style

The broad sphere of national life a sentence belongs to. Every sentence has an Arena, so it is the denominator the other indices are read against.

Other
  • Economic 37%35%
  • Social 28%27%
  • Ceremonial 17%17%
  • Geopolitical 11%10%
  • Technological 6%6%
  • Institutional 1%1%
  • Environmental 0%0%
  • Not in focus 3%

96 sentences in 23 paragraphs

Dear Mr. Weber,

dear Mr. Minister-President, dear Mr. Woidke,

Ambassador Yagi,

District Administrator,

Interior Minister and former District Administrator,

Mayor,

dear members of the federal and state parliaments,

above all: dear employees and trainees of Takeda,

Germany has – as we have often said, Mr. Ambassador – a great interest in expanding cooperation with Japan. The expansion of the Takeda plant in Oranienburg now shows how this can be done in practice. I am therefore very pleased to be present at the opening of the new production module.

During the tour, we have already gained some insights into the work here. We saw a state-of-the-art packaging line and – this is particularly exciting and currently in development – learned about the possibilities that 3D printing offers in the field of pharmaceuticals. The ability to produce spare parts or even print tablets ourselves today is something we did not foresee ten years ago. It is also highly interesting to see the various properties that different materials exhibit.

Digitalization is making its way into the healthcare sector just as it is in other areas. Therefore, it is timely that the federal government just held a digital summit in Ludwigshafen in Rhineland-Palatinate this week. The focus topic there was healthcare and digitalization. This is one facet of it. The range of topics extends from applications in hospitals, surgical techniques, telemedicine – which is particularly important for rural areas – to the introduction of health cards and changes in medical practices.

Oranienburg is a modern location for Takeda. I believe it is rightly referred to as a competence center. Medicines are produced here that are sent all over the world; Mr. Weber has outlined this for us. From here, you also support work at other locations – whether it is about new types of tablets, new packaging, or studies on the shelf life of medications. The investment in the production expansion that we can see here amounts to 100 million euros. This is a commitment from your company to the Oranienburg location, and at the same time, it is a commitment from the state of Brandenburg to the industrial development at this site.

I believe one reason for the decision to invest more here – we were just able to confirm this – is the skilled workforce. This once again shows how important training is. We, Mr. Minister-President Woidke and I, also talked about this with the trainees. I believe we can be quite proud in Germany that we have a very close integration of practical training and theoretical education in various professions. We are also firmly committed to strengthening vocational training even in the transformation brought about by digitalization. Digital changes must also be incorporated into the training of young people to foster young talent.

Securing the skilled workforce in Germany is, of course, a challenge. We will have fewer young people in the coming years. Therefore, it is all the more important that everyone has access to good training opportunities. However, we must also ensure that training is directed in the right ways. We are lacking many skilled workers in IT technologies. I can only warmly recommend to young people everything that arises in connection with digitalization and new job profiles. Because that has a future; skilled workers will be needed in Germany in that area. However, we must also provide our young people with excellent training opportunities.

Takeda is setting a good example in this regard, which is essential for the pharmaceutical location in Germany. At Takeda, you also know that one cannot start too early with talent acquisition. It is often about setting the first course during school age. Therefore, you have also established the Takeda-Runge Student Award this year. I find this an interesting initiative, as it encourages the ambition of young people to prove themselves in the natural sciences and achieve outstanding results. The namesake of the award is not only Takeda as a company but also the chemist Friedlieb Ferdinand Runge, whose 150th anniversary of death falls this year. He made a widely known name for himself through his long-standing work in Oranienburg. Thus, with the Takeda-Runge Student Award, you are also connecting to the tradition of this city as a center for chemistry and pharmaceuticals.

The foundation for local pharmaceutical production was laid 130 years ago by Heinrich Byk, who moved his factory from Berlin to Oranienburg at that time. I do not know what the reasons were, but he made a good choice. This also prepared the ground on which the company Takeda can build today. In the early days of German reunification, there must have been many hours of uncertainty for the employees. However, the then parent company of Byk Gulden, which was then Altana AG, decided in favor of the old headquarters. This led to the establishment of one of the most modern pharmaceutical plants in Europe. After various stages, Takeda now leads the plant. When Gerhard Schröder visited for a site expansion in 2005 with Matthias Platzeck, it still belonged to Altana AG. I am, of course, pleased that it has continued to progress well since then, and we can now say that the workforce has gradually grown to more than 700 employees today. This is already a significant number for this location. These are not just any jobs, but truly good and qualified jobs.

One can see at this location how much depends on whether a decision is made for or against an investment, and how many actually have to work together to ensure that a location can develop over years and decades – in this case, more than 100 years. Therefore, I may say on behalf of the federal government, just as the Brandenburg state government or the state governments of other federal states do, that Germany wants – we also know that Germany must – remain attractive for foreign investors. We are in a global competition. From Germany's perspective, we want an open, free, and fair competition. We do not believe in isolation or protectionism. We believe that this can bring only maximum short-term benefits, but that in the long run, we live in a mutual win-win situation when we engage with each other and cooperate.

We share this conviction with Japan. Japan has also increasingly taken this path. As economic partners, we have a common interest in open markets, whether it is about direct investments or trade. It is no coincidence that Japan was a partner country at CeBIT and other major German trade fairs. I work with Prime Minister Abe in this spirit. It is not by chance that the European Union is currently negotiating with Japan to conclude a trade agreement. We must and want to bring this to a conclusion, as our experience is that such trade agreements can increase the intensity of cooperation. We are not finished with the trade agreement yet, but Takeda has already taken a step further and invested in the healthcare sector at the German location.

The share of the healthcare sector in Germany has risen to twelve percent of our gross domestic product in the past five years. One can also say that this remains a future industry. The pharmaceutical share has not increased as dramatically – here we face tough global competition – but as a federal government, we have discussed with the pharmaceutical industry in Germany how we can keep the framework conditions attractive as part of the pharmaceutical dialogue. What I heard from Mr. Weber was also encouraging. We appreciate the innovative strength. However, we cannot say often enough how long it takes to develop new medications, which is why clear legal frameworks are needed, and that we must also invest in innovations overall.

Health research is one of the focal points of our high-tech strategy. The pharmaceutical dialogue, which I just mentioned, is also deliberately conducted not only with the economy and the government but, as is customary in the tradition of the social market economy, also with the relevant trade union, the IG BCE. The tradition of dialogue in the social market economy has led in Germany to the development of skilled workers and that many good developments have been achieved for employees and employers.

We need new medications time and again. One focus is, for example, the development of new antibiotics. We have made this a priority – we hold the G20 presidency this year and are hosting the G20 summit – together with the academies of sciences and the G20 member states. What many people today sometimes take for granted, that there will always be new medications, is not so self-evident in the case of antibiotics, because it is very, very difficult to develop new antibiotics. Therefore, it is also very important – Mr. Weber has also pointed this out – that we need a clear and good legal framework for the production of medications. We need reliability and also good protection against counterfeit medications. Therefore, we must continually work on the rules for medication supply, maintain contact with health insurance companies, and avoid supply shortages. You can see here how closely things are timed, how production can be adjusted according to demand, and how highly automated the whole process is. In this respect, we can and must meet the expectations of those who rely on medications.

Working on products that help people recover or stay healthy is, of course, an important task, where one can also report very well on the benefits and on what one does every day. Therefore, it does not surprise me that where I was able to gain a small insight, I saw highly motivated employees, to whom I wish much success and joy with the new production facility. I congratulate the management on this investment. I tell Mr. Ambassador that I take this as a good omen for German-Japanese cooperation.

I wish you all the best and much joy in utilizing the new opportunities.